December #184 : Prevention: Selzentry Is PrEP Contender - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

The POZ 100-Accelerating the End of AIDS

The POZ 100-The Seekers

The POZ 100-The Hunters

The POZ 100-The Defenders

The POZ 100-The Soldiers

The POZ 100-Cure All Glossary

Love is the Cure

From the Editor

More Than a Feeling

Feedback

Letters-December 2012

The POZ Q+A

Towards an HIV Cure

POZ Planet

A Very Big Kiki

Russians Deploy 'Google Bombs'

Home Alone

Say What-Paris Hilton

Back to School

What's a Buyers' Club? Matthew Knows.

iPad Video Game to Teach HIV Prevention Skills

Voices

Tried and True

Care and Treatment

One a Day to Keep Heart Attacks Away?

One Form to Rule Them All

Stribild is Here

T-Totaller

Nature's Little Helpers

GMHC Treatment Issues December 2012

Research Notes

Prevention: Selzentry Is PrEP Contender

Treatment: Dolutegravir Shows Promise

Cure: Curious Cohort on Early Treatment

Concerns: Fewer Comebacks From Heart Attacks

POZ Survey Says

Healthy Technology

POZ Heroes

Breaking Bad Cycles

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

December 2012

Prevention: Selzentry Is PrEP Contender

by Tim Horn

Is Selzentry (maraviroc) the next best pre-exposure prophylaxis, or PrEP, for HIV-negative individuals looking to avoid contracting the virus? A clinical trial dubbed NEXT-PrEP, which was announced in July, is looking to find out.   

Selzentry could be a useful alternative to Truvada, the only approved PrEP option, as it targets CD4 cells, not the virus. This potentially means less drug resistance—a concern for Truvada PrEP users who may need the drug, and others like it, if they later become infected.

Curiously, just one week after the clinical trial was announced, CDC scientists reported that maraviroc failed to protect monkeys from rectal infection with the virus. The results might not bode well for humans—only studies will tell—though NEXT-PrEP researchers say Selzentry doesn’t work as well on monkey cells as it does on human cells.


Search: Selzentry, NEXT PrEP, Truvada

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.